Cited by 640Parkinson's Disease Mechanisms and TreatmentsDeep Brain Stimulation and Movement DisordersNuclear Receptors and Signaling

The DOI matches its Crossref record; 238 of the 240 references it cites were found in a registry or an index.

Epidemiology of parkinson’s disease

Open access

Tanner, Caroline M., Goldman, Samuel M.·1996·Neurologic Clinics

DOI 10.1016/s0733-8619(05)70259-0PMC PMC7173037

Open this paper in CoChat — free account

Abstract

The epidemiologic studies reviewed here have provided insights into the etiology of PD. Evidence increasingly suggests that, like many other chronic age-related diseases, PD is a multifactorial disorder, with both genes and environment contributing to risk. As the elderly population of the world grows, incidence and prevalence of PD will continue to increase, underscoring the importance of further delineating risk factors. The introduction of levodopa and other pharmacologic therapies over the last 2 decades has postponed disease morbidity and mortality, but morbidity and mortality still are increased markedly relative to unaffected individuals. The development of therapies that may slow disease progression makes early identification and treatment of PD particularly important. Investigations of early markers of PD, or markers of disease susceptibility, are critical areas for future research. These efforts all will be aided by careful collaboration between epidemiologists and laboratory scientists.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s0733-8619(05)70259-0

Cites

238 of 238 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
An Essay on the Shaking Palsy
Parkinson, J. (2002) · Journal of Neuropsychiatry · doi:10.1176/jnp.14.2.223 · Cited by 2,856
Brain dopamine and the syndromes of Parkinson and Huntington Clinical, morphological and neurochemical correlations
Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K. A., & SEITELBERGER, F. (1973) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(73)90175-5 · Cited by 2,650
Case-Control Studies: Design, Conduct, Analysis.
Youkeles, L., & Schlesselman, J. J. (1983) · Journal of the American Statistical Association · doi:10.2307/2288156 · Cited by 2,358
Vitamin E Consumption and the Risk of Coronary Heart Disease in Men
Rimm, E. B., Stampfer, M. J., Ascherio, A., Giovannucci, E. L., Colditz, G. A., & Willett, W. C. (1993) · New England Journal of Medicine · doi:10.1056/nejm199305203282004 · Cited by 2,345
A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Burns, R. S., Chiueh, C. C., Markey, S. P., Ebert, M. H., Jacobowitz, D. M., & Kopin, I. J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.14.4546 · Cited by 2,149
Oxygen radicals and human disease
CROSS, C. E., HALLIWELL, B., BORISH, E. T., PRYOR, W. A., AMES, B. N., SAUL, R. L., McCORD, J. M., & HARMAN, D. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-4-526 · Cited by 1,856
Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects
Nehlig, A., Daval, J., & Debry, G. (1992) · Brain Research Reviews · doi:10.1016/0165-0173(92)90012-b · Cited by 1,463

Show all 240 references

Research works printed but not linked: 13

Breteler, 1995, Risk factors for Parkinson's disease: A population-based case-control study, Neurology, 45, A214
Campanella, 1990, Etiology of Parkinson's disease: Results of two case-control studies, Mov Disord, 5, 31
Davanipour, 1990, Residential histories in Parkinson's disease patients, Ann Neurol, 28, 295
Goetz, 1990, Motor vehicle accident and Parkinson's disease disability, Mov Disord, 5, 16
Kurth, 1995, Lack of association of CYP2D6 and MAO-B alleles with Parkinson's disease in a Kansas cohort, Neurology, 45, A429
Mjones, 1949, Paralysis agitans: A clinical and genetic study, Acta Psychiatry and Neurology, 54, 1
Rocca, 1990, Prevalence of Parkinson's disease and other parkinsonisms: A door-to-door survey in two Sicilian communities, Neurology, 40, 422
Tanner, 1989, Dietary antioxidant vitamins and the risk of developing Parkinson's disease, Neurology, 39, 181
Tanner, 1988, Vitamin use and Parkinson's disease, Ann Neurol, 233, 182
Treves, 1990, Case-control study, with use of temporal approach, for evaluation of risk factors for Parkinson's disease, Mov Disord, 5, 11
Uitti, 1991, Parkinsonism survival in the Levodopa era, Neurology, 41, 190
Vierregge, 1991, Parkinson's disease in twins, Neurology, 41, 255
Zimmerman, 1991, Parkinson's disease in monozygotic twins: A followup, Neurology, 41, 255

Sorted by citations

Items 401–500 of 640

Dentistry and Parkinson's disease: learnings from two case reports
Kaka, S., Lane, H., & Sherwin, E. (2019) · BDJ · doi:10.1038/s41415-019-0470-9 · Cited by 14
Exploring the complexity of EEG patterns in Parkinson’s disease
Nucci, L., Miraglia, F., Pappalettera, C., Rossini, P. M., & Vecchio, F. (2024) · GeroScience · doi:10.1007/s11357-024-01277-y · Cited by 13
Physiological and Biomechanical Analyses of Rigidity in Parkinson's Disease
Xia, R. (2011) · InTech eBooks · doi:10.5772/17849 · Cited by 13
The effect of crocin on movement disorders and oxidative DNA damage in Parkinson's disease: Insights from a randomized controlled trial
Soleymani, S. M., Assarzadegan, F., Habibi, S. A. H., Mahboubi, A., & Esmaily, H. (2024) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2024.107051 · Cited by 12
Application of fractal dimension on vestibular response signals for diagnosis of Parkinson's disease
Dastgheib, Z. A., Lithgow, B., & Moussavi, Z. (2011) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/iembs.2011.6091946 · Cited by 12
Does smoking reduce the risk of Parkinson’s disease through stimulation of the ubiquitin–proteasome system?
Chapman, M. A. (2009) · Medical Hypotheses · doi:10.1016/j.mehy.2009.03.053 · Cited by 12
Australian Parkinson’s Genetics Study (APGS): pilot (n=1532)
Bivol, S., Mellick, G. D., Gratten, J., Parker, R., Mulcahy, A., Mosley, P. E., Poortvliet, P. C., Campos, A. I., Mitchell, B. L., García‐Marín, L. M., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-052032 · Cited by 12
Treatment of Advanced Parkinsonʼs Disease in the United States
Groenendaal, H., Tarrants, M. L., & Armand, C. (2010) · Clinical Drug Investigation · doi:10.2165/11538520-000000000-00000 · Cited by 12
Effect of concurrent walking and interlocutor distance on conversational speech intensity and rate in Parkinson's disease
McCaig, C. M., Adams, S. G., Dykstra, A. D., & Jog, M. (2015) · Gait & Posture · doi:10.1016/j.gaitpost.2015.09.011 · Cited by 12
Prescribing Pattern for Parkinson’s Disease in Indian Community before Referral to Tertiary Center
Surathi, P., Kamble, N. L., Bhalsing, K. S., Yadav, R., & Pal, P. K. (2017) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2017.208 · Cited by 12
Sequential and concerted gene expression changes in a chronic in vitro model of parkinsonism
Greene, J. G., Greenamyre, J. T., & Dingledine, R. J. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.11.029 · Cited by 12
Pramipexole: a nonergot dopamine agonist as drug therapy in Parkinson’s disease
Hubble, J. P., & Novák, P. (2001) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.1.1.43 · Cited by 12
ICU management of patients with Parkinson's disease or Parkinsonism
Freeman, W. D., Tan, K. M., Glass, G. A., Linos, K. D., Foot, C. L., & Ziegenfuss, M. D. (2007) · Current Anaesthesia and Critical Care · doi:10.1016/j.cacc.2007.09.007 · Cited by 12
Novel Findings on CCR1 Receptor in CNS Disorders: A Pathogenic Marker Useful in Controlling Neuroimmune and Neuroinflammatory Mechanisms in Parkinson’s Disease
Repici, A., Capra, A. P., Hasan, A., Bulzomì, M., Campolo, M., Paterniti, I., Esposito, E., & Ardizzone, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084337 · Cited by 11
“In particular, PD affects about 0.5–1% of the world’s population aged between 65 and 69 years, increasing to up to 1–3% of people who are 80 or older [3].”
BackgroundInfluential
Novel Insights in Pharmacogenetics of Drug Response in Parkinson‘s Disease
Arbouw, M. E. L., Guchelaar, H., & Egberts, T. C. G. (2010) · Pharmacogenomics · doi:10.2217/pgs.09.175 · Cited by 11
Basal ganglia disorders
Melnick, M. E. (2013) · Elsevier eBooks · doi:10.1016/b978-0-323-07586-2.00029-7 · Cited by 13
Clinical Perspectives of Parkinson's Disease for Ophthalmologists, Otorhinolaryngologists, Cardiologists, Dentists, Gastroenterologists, Urologists, Physiatrists, and Psychiatrists
Choi, J.-H., Kim, J., Yang, H. K., Lee, H., Shin, C. M., Jeong, S. J., Kim, W., Han, J. W., Yoon, I., Song, Y. S., et al. (2020) · Journal of Korean Medical Science · doi:10.3346/jkms.2020.35.e230 · Cited by 11
Heterogenous response to aging of astrocytes in murine Substantia Nigra pars compacta and pars reticulata
Bondi, H., Chiazza, F., Masante, I., Bortolotto, V., Canonico, P. L., & Grilli, M. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2022.12.010 · Cited by 14
Silymarin versus Silibinin: Differential Antioxidant and Neuroprotective Effects against H 2 O 2 -induced Oxidative Stress in PC12 Cells
Jiang, H., Yan, F.-S., Shen, L., & Ji, H. (2016) · Natural Product Communications · doi:10.1177/1934578x1601100520 · Cited by 11
Parkinson's disease. Diagnosis and treatment.
Ng, D. C. (1996) · Europe PMC (PubMed Central) · Cited by 11
Rarity of debrisoquine hydroxylase gene polymorphism in chinese patients with Parkinson's disease
Pang, C. P., Zhang, J., Woo, J., Chan, D. K. Y., Law, L. K., Tong, S. F., Kwok, T. C. Y., & Kay, R. (1998) · Movement Disorders · doi:10.1002/mds.870130324 · Cited by 11
Dialkyldithiocarbamates inhibit tyrosine hydroxylase activity in PC12 cells and in fibroblasts that express tyrosine hydroxylase
Montine, T. J., Underhill, T. M., Valentine, W. M., & Graham, D. G. (1995) · Neurodegeneration · doi:10.1016/1055-8330(95)90017-9 · Cited by 11
Regulation of -Synuclein Expression: Implications for Parkinson's DiseasePreprint
Chiba‐Falek, O., & Nussbaum, R. L. (2003) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2003.68.409 · Cited by 11
Dirichlet process mixture models for unsupervised clustering of symptoms in Parkinson's disease
White, N., Johnson, H., Silburn, P., & Mengersen, K. (2012) · Journal of Applied Statistics · doi:10.1080/02664763.2012.710897 · Cited by 9
First-in-human transplantation of autologous induced neural stem cell-derived dopaminergic precursors to treat Parkinson’s disease
Chen, Z., & Zhao, G. (2023) · 中国科学通报：英文版 · doi:10.1016/j.scib.2023.10.020 · Cited by 10
Family History in Parkinson's Disease: A National Cross‐Sectional Study
Arienti, F., Casazza, G., Franco, G., Lazzeri, G., Monfrini, E., Maio, A. D., Erro, R., Barone, P., Tamma, F., Caputo, E., et al. (2024) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.14206 · Cited by 10
Fragility Fractures and Parkinsonism: Relationship of Fractures with Demography, Severity and Predictors of Adverse Outcomes
Aithal, S., Sequeira, R., Edwards, C., & Singh, I. (2017) · Geriatrics · doi:10.3390/geriatrics2020017 · Cited by 10
Association of Parkinson's disease with hospitalization for traumatic brain injury
Rumalla, K., Gondi, K. T., Reddy, A. Y., & Mittal, M. K. (2016) · International Journal of Neuroscience · doi:10.1080/00207454.2016.1239196 · Cited by 10
Potential Biomarkers for Parkinson Disease from Functional Enrichment and Bioinformatic Analysis of Global Gene Expression Patterns of Blood and Substantia Nigra Tissues
Elango, R., Banaganapalli, B., Mujalli, A., Alrayes, N. M., Almaghrabi, S. A., Almansouri, M., Sahly, A. N., Jadkarim, G. A., Malik, M. Z., Kutbi, H. I., et al. (2023) · Bioinformatics and Biology Insights · doi:10.1177/11779322231166214 · Cited by 10
Emerging approaches in Parkinson’s disease – adjunctive role of safinamide
Müller, T. H. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s86393 · Cited by 10
Imaging SERT Availability in a Rat Model of L-DOPA-Induced Dyskinesia
Walker, M., Kuebler, L., Goehring, C. M., Pichler, B. J., & Herfert, K. (2019) · Molecular Imaging and Biology · doi:10.1007/s11307-019-01418-2 · Cited by 10
Neuromodulation Approaches in Parkinson’s Disease Using Deep Brain Stimulation and Transcranial Magnetic Stimulation
Cleary, R. T., & Bucholz, R. D. (2021) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887211018269 · Cited by 10
Ocular features of patients with Parkinson’s disease examined at a Neuro-Optometry Clinic in a tertiary eye care center
Kwan, S. C. K., Atiya, A., Hussaindeen, J. R., Praveen, S., & Ambika, S. (2022) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_948_21 · Cited by 10
Structural studies of parkin and sacsin: Mitochondrial dynamics in neurodegenerative diseases
Li, X., & Gehring, K. (2015) · Movement Disorders · doi:10.1002/mds.26357 · Cited by 12
Juvenile parkinsonism
Uc, E. Y., & Rodnitzky, R. L. (2003) · Seminars in Pediatric Neurology · doi:10.1016/s1071-9091(02)00011-6 · Cited by 10
Screening of Crucial Cytosolicproteins Interconnecting the Endoplasmic Reticulum and Mitochondria in Parkinson’s Disease and the Impact of Anti-Parkinson Drugs in the Preservation of Organelle Connectivity
Anirudhan, A., Mahema, S., Ahmad, S. F., Emran, T. B., Ahmed, S. S. S. J., & Paramasivam, P. (2023) · Brain Sciences · doi:10.3390/brainsci13111551 · Cited by 9
“Parkinson’s disease (PD) is one of the most common movement disorders, characterized by the loss of dopamine-producing neurons in the midbrain’s Substantia nigra Brain Sci. 2023 , 13 region of the human brain [1].”
Background
Induction of GADD 45α protects M 17 neuroblastoma cells against MPP *
Wang, X., Zeng, Q., Zeng, Y. J., Man, R., Lu, B.-X., & Luo, Y. (2014) · IUBMB Life · doi:10.1002/iub.1327 · Cited by 9
Probabilistic subgroup identification using Bayesian finite mixture modelling: A case study in Parkinson's disease phenotype identification
White, N. M., Johnson, H., Silburn, P. A., Mellick, G. D., Dissanayaka, N. N., & Mengersen, K. L. (2010) · Statistical Methods in Medical Research · doi:10.1177/0962280210391012 · Cited by 9
Early Onset Parkinson’s Disease in a family of Moroccan origin caused by a p.A217D mutation in PINK1: a case report
Norman, B. P., Lubbe, S. J., Tan, M. M. X., Warren, N., & Morris, H. R. (2017) · BMC Neurology · doi:10.1186/s12883-017-0933-z · Cited by 9
Patterns and Predictors of Depression Treatment among Older Adults with Parkinson’s Disease and Depression in Ambulatory Care Settings in the United States
Bhattacharjee, S., Vadiei, N., Goldstone, L. W., Alrabiah, Z., & Sherman, S. J. (2018) · Parkinson s Disease · doi:10.1155/2018/3402983 · Cited by 9
Epigenetic Analysis in Human Neurons: Considerations for Disease Modeling in PD
de Boni, L., & Wüllner, U. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00276 · Cited by 8
“Parkinson’s disease (PD) is the second most common neurodegenerative disorder affecting 1–2% of the population aged>65 years (Tanner and Goldman, 1996).”
Background
Parkinsonism
Fahn, S., Jankovic, J. J., & Hallett, M. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-2369-4.00004-4 · Cited by 9
A study on risk factors for Parkinson’s disease in Indian population
Gupta, V., Garg, R. K., Pant, K. K., & Khattri, S. (2014) · Bioinformation · doi:10.6026/97320630010342 · Cited by 9
Clinical Profile of Parkinson's Disease: Experience of Niger
Assadeck, H., Daouda, M. T., Djibo, F. H., Maiga, D. D., & Omar, E. A. (2018) · Journal of Neurosciences in Rural Practice · doi:10.4103/jnrp.jnrp_337_17 · Cited by 9
Effectiveness of imaging genetics analysis to explain degree of depression in Parkinson’s disease
Won, J. H., Kim, M., Park, B., Youn, J., & Park, H. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211699 · Cited by 9
Modeling the cost-effectiveness and budgetary impact for subpopulations
Nuijten, M. J. C., Kosa, J., & Engelfriet, P. M. (2003) · The European Journal of Health Economics · doi:10.1007/s10198-002-0156-z · Cited by 9
“The existing patient-based Markov model for patients with Parkinson’s disease was extended to a populationbased model by incorporating health states for the normal French population without Parkinson's disease using incidence and prevalence data from the literature; the incidence data were transformed to a 6-month tra…”
Method
Profile of idiopathic parkinson’s disease in Moroccan patients
Regragui, W., Lachhab, L., Razıne, R., Raissouni, L., Rasmouni, K., Imounan, F., Benhaddou, E. H. A., Abouqal, R., Benomar, A., & Yahyaoui, M. (2014) · International Archives of Medicine · doi:10.1186/1755-7682-7-10 · Cited by 8
Dopamine Transporter SPECT Imaging in Parkinson Disease and Dementia
Surasi, D. S., Peller, P. J., Szabó, Z. R., Mercier, G., & Subramaniam, R. M. (2013) · PET Clinics · doi:10.1016/j.cpet.2013.08.006 · Cited by 8
Determination of metal elements concentrations in human brain tissues using PIXE and EDX methods
Pánik, J., Kopáni, M., Zeman, J., Jeskovsky, M., Kaizer, J., & Povinec, P. P. (2018) · Journal of Radioanalytical and Nuclear Chemistry · doi:10.1007/s10967-018-6208-3 · Cited by 8
Neuroprotective effect of neferine, an alkaloid against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced Parkinson's disease mouse model
Jing, S., Wang, Z., Zhang, J., Li, X., & Huang, R. (2021) · Pharmacognosy Magazine · doi:10.4103/pm.pm_291_19 · Cited by 8
Disease mechanisms as subtypes: Inflammation in Parkinson disease and related disorders
Standaert, D. G., Harms, A. S., Childers, G. M., & Webster, J. M. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85555-6.00011-4 · Cited by 8
Mitochondria and Parkinson's Disease
Simon, D. K., Chu, C. T., & Swerdlow, R. H. (2011) · Parkinson s Disease · doi:10.4061/2011/261791 · Cited by 8
A phase 2, open-label, multi-center study to evaluate the efficacy and safety of 99mTc-TRODAT-1 SPECT to detect Parkinson’s disease
Sun, Y., Liu, C., Chen, Z., Li, B., Lv, Z., Wang, J., Lou, J., Tang, J. T., Wang, Y.-K., Zhang, G., et al. (2019) · Annals of Nuclear Medicine · doi:10.1007/s12149-019-01412-2 · Cited by 8
Small ubiquitin-related modifier (SUMO) 3 and SUMO4 gene polymorphisms in Parkinson’s disease
Küçükali, C. İ., Yaylaz, B. S., Yüceer, H., Ulusoy, C. A., Abacı, N., Ekmekçi, S. S., Tüzün, E., Bılgıç, B., & Hanagasi, H. A. (2020) · Neurological Research · doi:10.1080/01616412.2020.1724464 · Cited by 8
“Parkinson’s disease (PD) is the second most common degenerative disorder of the central nervous system worldwide, with an estimated 7–10 million people affected [1].”
Background
Prevalence of Parkinsonism in Ansan-city
Koh, S., Kwon, D., Lee, J.-M., Han, J.-K., Kim, B., Park, M.-K., Park, K.-W., & Lee, D.-H. (2003) · Journal of the Korean Neurological Association · Cited by 8
Neuroprotection in Parkinson’s disease; a commentary
Gatto, E. M., Galdo, N. A. R., Carreras, M. C., Poderoso, J. J., & Micheli, F. E. (2002) · Neurotoxicity Research · doi:10.1080/10298420290015881 · Cited by 8
Editorial: Integrative Approach to Parkinson's Disease
Kim, S., Wang, X., & Park, H. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00339 · Cited by 8
“Emerging evidence indicates that PD is currently the second most common neurological disorder, with a prevalence of ∼1% among individuals aged 60–70 years, increasing to ∼3% among those aged 80 years and older (Tanner and Goldman, 1996; Nussbaum and Ellis, 2003).”
Background
Synthesis, crystal structure investigation and computational studies binding of (7S,8R)-7-acetyl-8-(4-chlorophenyl)-3-(ethylthio)-1,6-dimethyl-7,8-dihydroisoquinoline-4-carbonitrile with monoamine oxidase B
Bakhite, E. A.-G., Karthikeyan, S., Ahsin, A., Marae, I. S., Abdel-Rahman, A. E., Abuelhassan, S., Gad, M. A., Mohamed, S. K., Abuelizz, H. A., Mague, J. T., et al. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.137974 · Cited by 7
Gender-related differences in neuroscience – gender- and sex-related diseases
Prange, H. W. (2015) · Journal of Health Inequalities · doi:10.5114/jhi.2015.56819 · Cited by 7
Alpha synuclein (SNCA) rs7684318 variant contributes to Parkinson’s disease risk by altering transcription factor binding related with Notch and Wnt signaling
Naushad, S. M., Hussain, T., Alrokayan, S., & Kutala, V. K. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2021.135802 · Cited by 7
Parkinson's Disease: Symptoms and Age Dependency
Eshuis, S. A., & Leenders, K. L. (2001) · Elsevier eBooks · doi:10.1016/b978-012351830-9/50049-4 · Cited by 7
Occupational Characteristics and Patterns as Risk Factors for Parkinson’s Disease: A Case Control Study
Sullivan, K. L., Mortimer, J. A., Wang, W., Zesiewicz, T. A., Brownlee, H. J., & Borenstein, A. R. (2015) · Journal of Parkinson s Disease · doi:10.3233/jpd-150635 · Cited by 7
Dopaminergic differentiation using pluripotent stem cells
Momčilović, O., Montoya‐Sack, J., & Zeng, X. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24251 · Cited by 7
Classification of Parkinson’s disease Using Pitch Synchronous Speech Analysis
Appakaya, S. B., & Sankar, R. T. (2018) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc.2018.8512481 · Cited by 7
“Parkinson’s Disease (PD) is the second most common neurodegenerative disorder following Alzheimer’s disease [1].”
Background
Altered expression of voltage gated sodium channel Nav1.1 is involved in motor ability in MPTP-treated mice
Liu, W., Lao, W., Zhang, R., & Zhu, H. (2021) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2021.02.017 · Cited by 6
Entacapone in the management of Parkinson’s disease
Waters, C., & Henchcliffe, C. (2002) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.3.7.957 · Cited by 7
Inherited movement disorders
Sharma, N., & Standaert, D. G. (2002) · Neurologic Clinics · doi:10.1016/s0733-8619(01)00014-7 · Cited by 7
“It is a common disease, affecting about 3% of all individuals over the age of 65 years, amounting to an estimated 500,000 patients in the United States [26].”
Background
Role of Cellular Senescence in Parkinson’s Disease: Potential for Disease-Modification Through Senotherapy
Rademacher, D. J., Exline, J. E., & Foecking, E. M. (2025) · Biomedicines · doi:10.3390/biomedicines13061400 · Cited by 8
“The most important risk factor for PD is aging [26–28].”
A Comprehensive Study of miRNAs in Parkinson’s Disease: Diagnostics and Therapeutic Approaches
Siddique, Y. H., & Owais, S. (2022) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666220111152756 · Cited by 6
Movement Disorders
Winkel, D., & Bernstein, L. B. (2022) · Medical Clinics of North America · doi:10.1016/j.mcna.2022.02.002 · Cited by 6
Stereotaxic Intracranial Delivery of Chemicals, Proteins or Viral Vectors to Study Parkinson's Disease
Landeck, N., Mazza, M. C., Duffy, M. F., Bishop, C., Sortwell, C. E., & Cookson, M. (2021) · Journal of Visualized Experiments · doi:10.3791/62128 · Cited by 6
The assessment of executive functions to test the integrity of the nigrostriatal network: A pilot study
Ilardi, C., Maio, G. D., Villano, I., Messina, G., Monda, V., Messina, A., Porro, C., Panaro, M., Gamboz, N., Iavarone, A., et al. (2023) · Frontiers in Psychology · doi:10.3389/fpsyg.2023.1121251 · Cited by 6
Ionic Cocrystals of Levodopa and Its Biological Precursors l -Tyrosine and l -Phenylalanine with LiCl
Shemchuk, O., Braga, D., & Grepioni, F. (2019) · Crystal Growth & Design · doi:10.1021/acs.cgd.9b01003 · Cited by 6
Fas‐associated factor 1 induces the accumulation of α‐synuclein through autophagic suppression in dopaminergic neurons
Kim, B., Jang, T., Yoo, S., Lee, J. M., & Kim, E. (2021) · The FASEB Journal · doi:10.1096/fj.202001371rr · Cited by 6
The Parkinson Care Advocate: Integrating Care Delivery
Sokol, L. L., Shapiro, D., Young, M. J., Wise, A. H., Hadelsberg, U. P., Kaufman, Y., Espay, A. J., & Merola, A. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00364 · Cited by 6
Neural stimulation for Parkinson’s disease: current therapies and future directions
Neimat, J. S., Hamani, C., & Lozano, A. M. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.1.101 · Cited by 6
Entacapone, a catechol-O-methyltransferase inhibitor for treating Parkinson’s disease: review and current status
Gottwald, M. D. (1999) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.8.4.453 · Cited by 6
La apoptosis en las enfermedades neurodegenerativas: evidencias y controversias
Jiménez-Del-Río, M., & Velez‐Pardo, C. (2001) · Revista de Neurología · doi:10.33588/rn.3209.2000495 · Cited by 6
Is Endotoxin an Environmental Cause of Parkinson’s Disease?
Lange, J. H., Niehaus, I., & Thomulka, K. W. (2003) · Neuroepidemiology · doi:10.1159/000071196 · Cited by 6
The Possible Role of an Active Metafbollte Derived from the Neuroleptic Agent Haloperidol in Drug-Induced Parkinsonism
Igarashi, K. (1998) · Journal of Toxicology Toxin Reviews · doi:10.3109/15569549809006488 · Cited by 6
Role of Functional Neuroimaging with 123I-MIBG and 123I-FP-CIT in De Novo Parkinson’s Disease: A Multicenter Study
Feo, M. S. D., Frantellizzi, V., Locuratolo, N., Rocco, A. D., Farcomeni, A., Pauletti, C., Marongiu, A., Lazri, J., Nuvoli, S. M. F., Fattapposta, F., et al. (2023) · Life · doi:10.3390/life13081786 · Cited by 5
“The onset of PD before the age of 50 years is rare, with a significant increase in incidence after the age of 60 years [4].”
Background
Toxin Induced Mitochondrial Dysfunction and Neurodegeneration
Sabri, M. I. (1998) · Springer eBooks · doi:10.1007/978-3-662-12509-0_14 · Cited by 5
Using virtual environments to assess visual perception judgements in patients with Parkinson’s disease
Ou, Y., Lin, C., Fang, C.-W., & Liu, Y. (2018) · Transportation Research Part F Traffic Psychology and Behaviour · doi:10.1016/j.trf.2018.04.023 · Cited by 5
Mesenchymal Stem Cell–Derived Products for Tissue Repair and Regeneration
Srinivasan, A., Fults, M. L., Supronowicz, P., Esquivel, R., & Zamilpa, R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811920-4.00017-3 · Cited by 5
Susceptibility-weighted MR imaging (SWI) of basal ganglia iron deposition in the early and advanced stages of Parkinson's disease
Trufanov, A. G., Yurin, A. A., Buriak, A. B., Sandalov, S. A., Odinak, M. M., & Litvinenko, I. (2019) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2019-2-30-36 · Cited by 5
Studies on alpha-synuclein and islet amyloid polypeptide interaction
Wang, Y., Bergström, J. J. E., Ingelsson, M., & Westermark, G. T. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1080112 · Cited by 5
Progenitor endothelial cell involvement in Alzheimer's disease
Budinger, T. F. (2003) · Neurological Research · doi:10.1179/016164103101202066 · Cited by 5
The prevalence of Parkinson’s disease among Vilnius inhabitants
Valeikienė, V., Čeremnych, J., Mieliauskaitė, D., & Alekna, V. (2008) · Open Medicine · doi:10.2478/s11536-008-0014-1 · Cited by 5
Parkinson's Disease
Caspi, O., & Thomson, C. A. (1999) · Integrative medicine · doi:10.1016/s1096-2190(99)00006-2 · Cited by 5
“Untangling” the relationship between Alzheimer disease and dementia with Lewy bodies
Swerdlow, R. H., & Newell, K. L. (2012) · Neurology · doi:10.1212/wnl.0b013e3182735ecf · Cited by 5
Plant-derived neuroprotective compounds and nanoformulations targeting Parkinson’s disease: a semi-systematic review of mechanisms and therapeutic potential
Saraswathi, S., Venkataravanappa, J. T., Nambiar, C., Saji, S., Kori, V., Murthy, M. N., Somanna, P., Suresh Babu, S. V., Sreeramulu, A. K., Dayalan, A., et al. (2026) · Metabolic Brain Disease · doi:10.1007/s11011-026-01868-y · Cited by 4
Guardians of the temporomandibular joint: The occlusal splints- an overview
Eshwar, P., Swetha, M. U., Rao, S., Ashok, K., Sarkar, S. M., & Jyothi, S. (2023) · Archives of Dental Research · doi:10.18231/j.adr.2022.012 · Cited by 4
Neuroprotective Therapy in Parkinson's Disease: Current Status and New Directions from Experimental and Genetic Clues
Lin, W., & Kang, U. J. (2005) · Journal of Clinical Neurology · doi:10.3988/jcn.2005.1.2.107 · Cited by 4
Escenas en movimiento. Los trastornos del movimiento en el cine
Romero, J. O. (2010) · Neurología · doi:10.1016/s0213-4853(10)70035-9 · Cited by 4
Bone Quality in Patients with Parkinson’s Disease Determined by Quantitative Ultrasound (QUS) of the Calcaneus: Influence of Sex Differences
Caplliure‐Llopis, J., Escrivá, D., Navarro-Illana, E., Benlloch, M., Ortí, J. E. D. L. R., & Barrios, C. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19052804 · Cited by 4
An Overview of Parkinson's Disease and Oxidative Stress: Herbal Scenario
Jayaraj, R. L., Ravindar, D. J., Manigandan, K., Padarthi, P. K., & Elangovan, N. (2012) · Neuropathological diseases · doi:10.1615/neuropatholdiseases.v1.i2.10 · Cited by 4
Magnetic resonance imaging (MRI) methods in Parkinson's disease
Mangia, S., Michaeli, S., & Tuite, P. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139207294.003 · Cited by 4
Unlocking ferulic acid for neurological diseases and tailoring of nanoformulations to advance its brain delivery
de Andrade, P. R. A., Motta, R. C., & Fonseca‐Santos, B. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126173 · Cited by 4
“Going Backward”: Effects of age and fatigue on posterior-directed falls in Parkinson disease
Papa, E. V., Patterson, R. M., & Bugnariu, N. (2021) · Neurorehabilitation · doi:10.3233/nre-210040 · Cited by 5
Relative frequencies of neurological disorders in Northwestern Nigeria: A retrospective study
Balarabe, S., & Kamfani, J. (2019) · Annals of African Medicine · doi:10.4103/aam.aam_13_18 · Cited by 3

Authors: Tanner, C. M., & Goldman, S. M.
Affiliations: Parkinson's Institute and Clinical Center (US)
ORCID: Tanner, Caroline M.
Goldman, Samuel M.
Venue: Neurologic Clinics
Publisher: Elsevier BV
Published: 1996-05
Volume: 14
Issue: 2
Pages: 317-335
ISSN: 0733-8619 (ISSN-L)
DOI: 10.1016/s0733-8619(05)70259-0
PMC: PMC7173037
OpenAlex: W2084553926
Semantic Scholar: 722f96a983f226977773068a6a70c00979c0cbd5
Cited by: 640
References: 240
Citations by year: 2026: 9 · 2025: 10 · 2024: 17 · 2023: 29 · 2022: 23 · 2021: 26 · 2020: 14 · 2019: 24 · 2018: 35 · 2017: 36 · 2016: 28 · 2015: 26 · 2014: 32 · 2013: 28 · 2012: 19
FWCI: 11.14
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Neurologic Clinics (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (R01CA094089)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Keywords: Parkinson's disease, etiology, complex diseases, genetic risk factors, environmental risk factors, incidence, prevalence, levodopa, early markers, disease susceptibility, disease progression
MeSH terms: Aged, Consanguinity, Diet, Environmental Exposure, Female, Humans, Male, Middle Aged, Parkinson Disease, Risk Factors, Smoking, Global Health, Hazardous Substances, Incidence, Prevalence, Age Distribution, Sex Distribution, Patient Selection

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Epidemiology of parkinson’s disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks